Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical mechanisms and preclinical targets with no human clinical trial data.
PubMed 38921477 · doi:10.3390/metabo14060343
What was done
This narrative review synthesized the mechanistic role of nicotinamide N-methyltransferase (NNMT) in biological aging and age-associated pathologies, focusing on metabolic pathways and early experimental interventions using small-molecule inhibitors and RNA interference (RNAi).
What was found
The abstract reports no quantitative metrics or effect sizes. Mechanistically, NNMT utilizes S-adenosylmethionine (SAM) to methylate nicotinamide (NAM), yielding methylnicotinamide (MNA) and S-adenosyl-L-homocysteine (SAH). This enzymatic action depletes NAM (a key precursor for NAD+ biosynthesis) and elevates SAH (a precursor to homocysteine), both implicated in the progression of aging. Early RNAi and small-molecule NNMT inhibitors demonstrate therapeutic potential in preclinical models, but precise downstream mechanisms remain unclarified.
Why it matters
Modulating NNMT activity represents a potential upstream strategy to maintain NAD+ levels and mitigate homocysteine toxicity in aging, distinct from direct NAD+ supplementation.
Limits
The paper is a non-systematic narrative review based solely on preclinical and mechanistic literature. There are currently no completed human clinical trials evaluating NNMT inhibitors or RNAi drugs for age-related conditions.
Cited by
- supports High levels of NAD clearance through NNMT consume methyl groups and reduce SAMe.